The drug, ALX-0081, uses the company’s Nanobody technology to target to reduce the risk of thrombosis in patients with acute coronary syndrome.
The phase I study in healthy volunteers is designed to assess safety, tolerability and pharmacokinetics of ALX-0081. It will also analyze pharmacodynamic effects of ALX-0081 to confirm its high potency. It is a double-blind, placebo-controlled trial in healthy male volunteers at a single center in Europe.
The study was initiated during the first quarter of 2007. The interim analysis indicates that the desired pharmacodynamic effect was observed as anticipated and ALX-0081 was well tolerated and showed no serious adverse effects or dose limiting toxicity.
The final results are expected to be available by the end of September 2007.
Dr Edwin Moses, CEO and chairman, said: “We are very encouraged by the positive results of our first Nanobody in clinical development which is believed to be the first ever single domain antibody human trial. This is a significant milestone for Ablynx and demonstrates the success of Ablynx’s powerful discovery platform.”